Expression of PIM kinase and antiapoptotic proteins and transcript levels in healthy and chronic lymphocytic leukemia (CLL) lymphocytes. (A) Protein expression of PIM1, PIM2, and PIM3 in untreated healthy and CLL primary cells. Lymphocytes from healthy donors and CLL patients were lysed and analyzed by immunoblot for PIM kinases with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a loading control. (B) mRNA levels of PIM1, PIM2, and PIM3 in untreated healthy and CLL primary cells. Lymphocytes from healthy donors and CLL patients were lysed and analyzed by real time reverse transcription polymerase chain reaction for the PIM kinases with eukaryotic 18S ribosomal RNA used as an internal control. (C) Protein expression of MCL-1, BCL-X L , and BCL-2 in untreated healthy and CLL primary cells. Lymphocytes from healthy donors and CLL patients were lysed and analyzed by immunoblot for the three antiapoptotic proteins, with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a loading control. (D) mRNA levels of MCL-1, BCL-X L , and BCL-2 in untreated healthy and CLL primary cells. Lymphocytes from healthy donors and CLL patients were lysed and analyzed by real time reverse transcription polymerase chain reaction for the three antiapoptotic proteins, with eukaryotic 18S ribosomal RNA used as an internal control. Note: GAPDH loading control in Supplementary Figure 1A and 1C is the same.
Supplementary Figure 2:
Impact of different types of serum on AZD1208-induced apoptosis in chronic lymphocytic leukemia (CLL) cells. CLL lymphocytes from seven CLL patients were collected and cultured in media supplemented with 10% fetal bovine serum (FBS), 10% human serum (human), or 10% autologous serum (autologous). Each sample was treated with either dimethyl sulfoxide (DMSO) (0.1%), 3 µM, or 10 µM AZD1208 for 24 h and cell death was determined using flow cytometry after Annexin V/ propidium iodide (PI) staining.
